Skip to main content
SpringerLink
Log in

Therapy Response Imaging in Thoracic Malignancy

  • Chapter
  • First Online:
Therapy Response Imaging in Oncology

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 681 Accesses

Abstract

Lung cancer remains to be the leading cause of cancer death. More than half of patients with lung cancer present with advanced disease requiring systemic therapy. Remarkable advances of systemic therapy approaches have been made for patients with advanced lung cancer in the past decade, first with molecular targeting therapy that can specifically target genomic driver mutations of the tumor, and more recently with immune-checkpoint inhibitors that activate host T cell immune response against tumor. The strategies for radiographic tumor response evaluations for lung cancer have also evolved in parallel with the advances of treatment approaches for the disease. This chapter will discuss (1) recent advances of therapeutic approaches for lung cancer, (2) imaging for treatment monitoring for lung cancer in the era of precision cancer therapy, and (3) treatment monitoring of thoracic malignancies other than lung cancer, focusing on thymic tumors and malignant pleural mesothelioma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Antonia SJ, Villegas A, Daniel D et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Article  CAS  PubMed  Google Scholar 

  • Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342–2350

    Article  CAS  PubMed  Google Scholar 

  • Armato SG 3rd, Nowak AK (2018) Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (version 1.1). J Thorac Oncol 13:1012–1021

    Article  PubMed  Google Scholar 

  • Benveniste MF, Korst RJ, Rajan A, Detterbeck FC, Marom EM (2014) A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol 9:S119–S124

    Article  PubMed  Google Scholar 

  • Benveniste MF, Rosado-de-Christenson ML, Sabloff BS, Moran CA, Swisher SG, Marom EM (2011) Role of imaging in the diagnosis, staging, and treatment of thymoma. Radiographics 31:1847–1861; discussion 1861–1843

    Article  PubMed  Google Scholar 

  • Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123–135

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Breathnach OS, Freidlin B, Conley B et al (2001) Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19:1734–1742

    Article  CAS  PubMed  Google Scholar 

  • Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Carter BW, Benveniste MF, Madan R et al (2017) IASLC/ITMIG staging system and lymph node map for thymic epithelial neoplasms. Radiographics 37:758–776

    Article  PubMed  Google Scholar 

  • Champiat S, Dercle L, Ammari S et al (2017) Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23:1920–1928

    Article  CAS  PubMed  Google Scholar 

  • Costa DB, Shaw AT, Ou SH et al (2015) Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33:1881–1888

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Crabb SJ, Patsios D, Sauerbrei E et al (2009) Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. J Clin Oncol 27:404–410

    Article  CAS  PubMed  Google Scholar 

  • Detterbeck FC, Stratton K, Giroux D et al (2014) The IASLC/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors. J Thorac Oncol 9:S65–S72

    Article  PubMed  Google Scholar 

  • Eberlein CA, Stetson D, Markovets AA et al (2015) Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models. Cancer Res 75:2489–2500

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ferrara R, Mezquita L, Texier M et al (2018) Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 4:1543–1552

    Article  PubMed  PubMed Central  Google Scholar 

  • Gandhi L, Rodriguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092

    Article  CAS  PubMed  Google Scholar 

  • Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018–2028

    Article  PubMed  Google Scholar 

  • Gazdar AF (2009) Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 361:1018–1020

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gettinger SN, Horn L, Gandhi L et al (2015) Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 33:2004–2012

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goss G, Tsai CM, Shepherd FA et al (2016) Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 17:1643–1652

    Article  CAS  PubMed  Google Scholar 

  • Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359:1367–1380

    Article  CAS  PubMed  Google Scholar 

  • Isozaki H, Ichihara E, Takigawa N et al (2016) Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res 76(6):1506–1516

    Article  CAS  PubMed  Google Scholar 

  • Janne PA, Gurubhagavatula S, Yeap BY et al (2004) Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer 44:221–230

    Article  PubMed  Google Scholar 

  • Janne PA, Yang JC, Kim DW et al (2015) AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 372:1689–1699

    Article  PubMed  Google Scholar 

  • Johnson BE (2016) Divide and conquer to treat lung cancer. N Engl J Med 375:1892–1893

    Article  PubMed  Google Scholar 

  • Khandelwal A, Sholl LM, Araki T, Ramaiya NH, Hatabu H, Nishino M (2016) Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes. Clin Radiol 71:1010–1017

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kim TM, Song A, Kim DW et al (2015) Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol 10:1736–1744

    Article  CAS  PubMed  Google Scholar 

  • Kindler HL, Ismaila N, Armato SG 3rd et al (2018) Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 36:1343–1373

    Article  PubMed  Google Scholar 

  • Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee HY, Lee KS, Ahn MJ et al (2011) New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer 73:63–69

    Article  PubMed  Google Scholar 

  • Lee JH, Lee HY, Ahn MJ et al (2016) Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study. Cancer Imaging 16:5

    Article  PubMed  PubMed Central  Google Scholar 

  • Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139

    Article  CAS  PubMed  Google Scholar 

  • Marom EM, Martinez CH, Truong MT et al (2008) Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer. J Thorac Oncol 3:351–357

    Article  PubMed  Google Scholar 

  • Mok TS (2010) Living with imperfection. J Clin Oncol 28:191–192

    Article  CAS  PubMed  Google Scholar 

  • Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  CAS  PubMed  Google Scholar 

  • Mozley PD, Bendtsen C, Zhao B et al (2012) Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. Transl Oncol 5:19–25

    Article  PubMed  PubMed Central  Google Scholar 

  • Nickell LT Jr, Lichtenberger JP 3rd, Khorashadi L, Abbott GF, Carter BW (2014) Multimodality imaging for characterization, classification, and staging of malignant pleural mesothelioma. Radiographics 34:1692–1706

    Article  PubMed  Google Scholar 

  • Nishino M (2018) Tumor response assessment for precision cancer therapy: response evaluation criteria in solid tumors and beyond. Am Soc Clin Oncol Educ Book 38:1019–1029

    Article  PubMed  Google Scholar 

  • Nishino M, Ashiku SK, Kocher ON, Thurer RL, Boiselle PM, Hatabu H (2006) The thymus: a comprehensive review. Radiographics 26:335–348

    Article  PubMed  Google Scholar 

  • Nishino M, Cardarella S, Dahlberg SE et al (2013c) Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer 79:283–288

    Article  PubMed  Google Scholar 

  • Nishino M, Cryer SK, Okajima Y et al (2012b) Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab. Cancer Imaging 12:225–235

    Article  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Dahlberg SE, Adeni AE et al (2017b) Tumor response dynamics of advanced non-small cell lung cancer patients treated with PD-1 inhibitors: imaging markers for treatment outcome. Clin Cancer Res 23:5737–5744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Dahlberg SE, Cardarella S et al (2013a) Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol 8:1059–1068

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Dahlberg SE, Cardarella S et al (2013b) Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer 119:3761–3768

    Article  CAS  PubMed  Google Scholar 

  • Nishino M, Dahlberg SE, Fulton LE et al (2016) Volumetric tumor response and progression in EGFR-mutant NSCLC patients treated with erlotinib or gefitinib. Acad Radiol 23:329–336

    Article  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS (2013d) Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res 19:3936–3943

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Giobbie-Hurder A, Manos MP et al (2017c) Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: identifying markers for clinical outcome and treatment decisions. Clin Cancer Res 23:4671–4679

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Guo M, Jackman DM et al (2011b) CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol 18:54–62

    Article  PubMed  Google Scholar 

  • Nishino M, Hatabu H, Hodi FS (2019) Imaging of cancer immunotherapy: current approaches and future directions. Radiology 290:9–22

    Article  PubMed  Google Scholar 

  • Nishino M, Hatabu H, Johnson BE, McLoud TC (2014) State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology 271:6–27

    Article  PubMed  Google Scholar 

  • Nishino M, Jackman DM, Hatabu H, Janne PA, Johnson BE, Van den Abbeele AD (2011a) Imaging of lung cancer in the era of molecular medicine. Acad Radiol 18:424–436

    Article  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Jagannathan JP, Krajewski KM et al (2012a) Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST. AJR Am J Roentgenol 198:737–745

    Article  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Ramaiya NH, Hatabu H, Hodi FS (2017a) Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol 14:655–668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nishino M, Wakai S, Hida T et al (2018) Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol 109:68–76

    Article  PubMed  PubMed Central  Google Scholar 

  • Ortiz-Cuaran S, Scheffler M, Plenker D et al (2016) Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res 22:4837–4847

    Article  CAS  PubMed  Google Scholar 

  • Ou SH, Ahn JS, De Petris L et al (2016) Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–668

    Article  CAS  PubMed  Google Scholar 

  • Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500

    Article  CAS  PubMed  Google Scholar 

  • Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306–13311

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Park H, Sholl LM, Hatabu H, Awad MM, Nishino M (2019) Imaging of precision therapy for lung cancer: current state of the art. Radiology 293(1):15–29

    Article  PubMed  Google Scholar 

  • Park K, Yu CJ et al (2016) First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol 2(3):305–312

    Article  PubMed  Google Scholar 

  • Paz-Ares L, Luft A, Vicente D et al (2018) Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med 379:2040–2051

    Article  CAS  PubMed  Google Scholar 

  • Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838

    Article  CAS  PubMed  Google Scholar 

  • Radovich M, Pickering CR, Felau I et al (2018) The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 33:244–258. e210

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ready N, Farago AF, de Braud F et al (2019) Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol 14(2):237–244

    Article  PubMed  CAS  Google Scholar 

  • Reck M, Rodriguez-Abreu D, Robinson AG et al (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

    Article  CAS  PubMed  Google Scholar 

  • Riely GJ, Kris MG, Zhao B et al (2007) Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 13:5150–5155

    Article  CAS  PubMed  Google Scholar 

  • Rizvi NA, Mazieres J, Planchard D et al (2015) Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 16:257–265

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Russo AE, Priolo D, Antonelli G, Libra M, McCubrey JA, Ferrau F (2017) Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer (Auckl) 8:259–269

    CAS  Google Scholar 

  • Salvador-Coloma C, Lorente D, Palanca S et al (2018) Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. J Thorac Dis 10:1386–1393

    Article  PubMed  PubMed Central  Google Scholar 

  • Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550

    Article  CAS  PubMed  Google Scholar 

  • Shaw AT, Gandhi L, Gadgeel S et al (2016) Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–242

    Article  CAS  PubMed  Google Scholar 

  • Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394

    Article  CAS  PubMed  Google Scholar 

  • Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34

    Article  PubMed  Google Scholar 

  • Socinski MA, Jotte RM, Cappuzzo F et al (2018) Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med 378:2288–2301

    Article  CAS  PubMed  Google Scholar 

  • Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177

    Article  PubMed  CAS  Google Scholar 

  • Soria JC, Ohe Y, Vansteenkiste J et al (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125

    Article  CAS  PubMed  Google Scholar 

  • Takeda M, Okamoto I, Nakagawa K (2014) Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. J Thorac Oncol 9:200–204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tani T, Yasuda H, Hamamoto J et al (2016) Activation of EGFR bypass signaling by TGFalpha overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells. Mol Cancer Ther 15:162–171

    Article  CAS  PubMed  Google Scholar 

  • Wolchok JD, Hoos A, O’Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412–7420

    Article  CAS  PubMed  Google Scholar 

  • Zhao B, James LP, Moskowitz CS et al (2009) Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 252:263–272

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735–742

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA

    Mizuki Nishino

  2. Department of Radiology, Brigham and Women’s Hospital, Boston, MA, USA

    Mizuki Nishino

Authors
  1. Mizuki Nishino
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mizuki Nishino .

Editor information

Editors and Affiliations

  1. Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Mizuki Nishino

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Nishino, M. (2020). Therapy Response Imaging in Thoracic Malignancy. In: Nishino, M. (eds) Therapy Response Imaging in Oncology. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/978-3-030-31171-1_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-31171-1_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-31170-4

  • Online ISBN: 978-3-030-31171-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation